arrow
R

Robert Z. Orlowski

Department of Lymphoma and Myeloma
H指数:101
被引数:5.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

在复发多发性骨髓瘤中,自体移植后使用达鲁单抗±泊马利度胺进行维持治疗:一项2期研究

2026-09-260
OAAI
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
D-VRD induction and autologous transplant in patients ≥70 years

D-VRD诱导和自体移植在≥70岁患者中的应用

2026-06-050
OAAI
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE

达拉妥单抗治疗新诊断多发性骨髓瘤患者的感染:MAIA和ALCYONE研究的合并分析

2026-05-070
OAAI
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

遗传血统与复发/难治性多发性骨髓瘤患者接受伊decabtagene vicleucel治疗后结局和毒性的关联

2026-04-130
OAAI
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: Dynamics of MRD-negativity in the IMROZ study

Isatuximab,bortezomib,lenalidomide,dexamethasone用于多发性骨髓瘤:IMROZ研究中MRD阴性的动态变化

Blood
IF23.1
2026-03-030
OA
Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation

来那度胺维持治疗在延迟或挽救性自体造血干细胞移植后的应用

2026-01-010
PRE
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma

延迟或挽救性自体造血干细胞移植治疗多发性骨髓瘤的结果

2025-12-050
PRE
Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy

Waldenström巨球蛋白血症患者停止Bruton酪氨酸激酶抑制剂(BTKi)治疗后的长期结局及治疗模式

2025-12-030
OAAI
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans

黑人美国人和白人美国人在多发性骨髓瘤患者适当匹配时的生存率相同

2025-10-160
OA
Corrigendum to “Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states” [Neoplasia 66 (2025) 1101189]

勘误表:“Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states” [Neoplasia 66 (2025) 1101189]

2025-09-060
PREAI
Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

作者更正:造血干细胞自体移植后的克隆性进化

2025-08-110
OAAI
Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant

多发性骨髓瘤患者伴有1p缺失行自体干细胞移植后的结局

2025-08-050
PRE
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

Isatuximab在多发性骨髓瘤治疗中的应用:当前临床进展与未来方向

2025-07-230
OA
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

自体干细胞移植后造血干细胞的克隆进化

2025-07-010
OA